Sign in
Taking peopleNo phase

The Effect of Remimazolam Tosylate on the Incidence of Postoperative Delirium in Older Patients Undergoing Cardiac Surgery: A Prospective Randomized Controlled Trial

Key facts

Who runs it
Nanjing First Hospital, Nanjing Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
600 people, planned
Started
5 Sept 2026
Expected to end
30 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Remimazolam Tosylate
  • Propofol
Record updated
30 October 2026

Who can take part

Age
65 years to 90 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age ≥65 years. 2. Undergoing elective cardiac surgery with cardiopulmonary bypass, including coronary artery bypass grafting (CABG), valve surgery, or combined CABG and valve surgery
  • Admission to the cardiac surgery intensive care unit (ICU) after surgery, with an anticipated need for invasive mechanical ventilation and continuous sedation for at least 2 hours
  • Written informed consent obtained from the participant or their legally authorized representative
  • No delirium identified during the preoperative assessment. Exclusion Criteria
  • Emergency or salvage cardiac surgery
  • Heart transplantation, ventricular assist device implantation, surgery for aortic dissection requiring deep hypothermic circulatory arrest, or other cardiac procedures outside the scope of this study
  • Severe psychiatric disorders, diagnosed Alzheimer's disease or dementia, or preoperative delirium
  • Severe alcohol use disorder or a history of severe alcohol misuse
  • Previous cerebrovascular events or other conditions causing severe visual, hearing, or communication impairment that would prevent reliable delirium assessment despite appropriate assistance
  • Known hypersensitivity or contraindications to either study drug or its excipients, or severe hepatic or renal failure
  • Decompensated acute circulatory failure or hemodynamic instability at the time of randomization
  • Concurrent participation in another interventional clinical trial that could affect the primary outcome

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 65 and 90 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to compare the efficacy and safety of remimazolam tosylate and propofol for postoperative sedation in patients aged 65 years or older undergoing cardiac surgery with cardiopulmonary bypass. Postoperative delirium (POD) is a common complication in older patients after cardiac surgery and may adversely affect postoperative recovery and clinical outcomes. Whether remimazolam tosylate reduces the incidence of POD compared with propofol under standardized sedation and analgesia protocols remains uncertain.

Read full original descriptionShow less

This is a single-center, prospective, randomized, double-blind, double-dummy, active-controlled superiority trial. A total of 600 eligible patients will be randomized in a 1:1 ratio to receive remimazolam tosylate or propofol for continuous sedation in the cardiac surgery intensive care unit (ICU). In both groups, the infusion rate will be titrated to maintain a target Richmond Agitation-Sedation Scale (RASS) score of -2 to 0, with standardized analgesia and postoperative care.

The primary outcome is the incidence of POD within 7 days after surgery. Delirium will be assessed using the Confusion Assessment Method for the ICU (CAM-ICU) in patients who are intubated or unable to communicate verbally, and the Chinese version of the 3-Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM-CN) in patients who are able to communicate.

Secondary clinical outcomes include time to first delirium, delirium duration and severity, achievement of the target sedation level, pain scores, rescue sedative use, time to extubation, ICU length of stay, hospital length of stay, and safety outcomes, including hypotension, bradycardia, and vasopressor use.

This study aims to determine whether remimazolam tosylate reduces the incidence of POD compared with propofol in older patients after cardiac surgery. The findings may provide clinical evidence to guide postoperative sedative selection and help improve delirium prevention and postoperative recovery in this population.

The 2 groups in the trial

  • Remimazolam tosylateTreatment being tested
  • PropofolExisting treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of Remimazolam Tosylate Versus Propofol for Postoperative Sedation on the Incidence of Postoperative Delirium in Older Patients Undergoing Cardiac Surgery: A Prospective, Double-Blind, Randomized Controlled Trial
Criteria questions
Built from NCT07908121, who can take part
Record updated
30 October 2026